

July 21, 2023

National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHPHARMA**

Scrip Code: 524372

Subject: Reconciliation of Share Capital Audit Report

Dear Sir/Madam,

Pursuant to Regulation 76 of Securities and Exchange Board of India (Depositories & Participants) Regulations, 2018, please find enclosed herewith copy of the Reconciliation of Share Capital Audit Report for the quarter ended June 30, 2023 duly certified by a Company Secretary in practice.

You are requested to take the above intimation on record.

Thanking You,
For **Orchid Pharma Limited**

Marina Peter
Company Secretary & Compliance Officer
Encl. as above

RECONCILIATION OF SHARE CAPITAL AUDIT

To,

The Board of Directors,

ORCHID PHARMA LIMITED

“Orchid Towers”, 313, Valluvar Kottam High Road,
Nungambakkam, Chennai – 600034.

We have examined the Register of Members, beneficiary details furnished by the Depositories and other records/ documents maintained by **Orchid Pharma Limited** hereinafter referred to as (“the Company”) and its Registrars and Share Transfer Agents, **Abhipra Capital Limited**, for issuing this certificate, in accordance with Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

In our opinion and to the best of our knowledge and according to the information and explanations given to us and based on such verification as considered necessary, we hereby certify the following in respect of the quarter end ended **30th June, 2023**.

1.	For Quarter Ended	30 th June, 2023	
2.	ISIN	INE191A01027	
3.	Face Value	Rs.10/-	
4.	Name of the Company	Orchid Pharma Limited	
5.	Registered Office Address	“Orchid Towers”, 313, Valluvar Kottam High Road Nungambakkam, Chennai - 600034	
6.	Correspondence Address	“Orchid Towers”, 313, Valluvar Kottam High Road, Nungambakkam, Chennai - 600034	
7.	Telephone & Fax Nos.	Phone: (044) - 28211000 Fax: (044) – 2821 1002	
8.	Email address	corporate@orchidpharma.com	
9.	Name of the stock exchange where the company securities are listed:	BSE Limited and National Stock Exchange Limited	
10.	Issued Capital	Number of shares	% of Total Issued Cap.
		5,07,19,105	100%
11.	Listed Capital (Exchange-wise)	4,08,16,400	80.47%
12.	Held in dematerialised form in CDSL	3,89,81,933	76.86%

13.	Held in dematerialised form in NSDL	18,30,945	3.61%				
14.	Physical	3,522	0.00 %				
15.	Total No. of shares (12+13+14)	4,08,16,400	80.47%				
16.	Reasons for difference if any, between (10&11) , (10&15) , (11&15) :	On June 27,2023 the Board of Directors issued and allotted 99,02,705 Equity Shares of Rs. 10/- Each to eligible Qualified Institutional Buyers. Therefore the Paid up Capital of the Company increased from 40,81,64,000 to 50,71,91,050 w.e.f. June 27, 2023.					
17.	Certifying the details of changes in share capital during the quarter end under consideration as per table below :						
	Particulars	No. of shares	Applied /Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Approval pending for SE (Specify Names)
	Allotment of 9,902,705 Equity Shares of face value ₹ 10 each to eligible qualified institutional buyers on Qualified Institutional Placement basis	99,02,705 Equity Shares	Applied	Please refer to note below	Yes	Yes	NA
	<i>Note: The Board of Directors issued and allotted 9,902,705 Equity Shares of face value ₹ 10 each on QIP basis on June 27, 2023. The listing approval was received on June 30, 2023. Trading was effective from July 03, 2023.</i>						
18.	Register of Members is updated (Yes / No) If not, updated up to which date.	YES					
19.	Reference of previous quarter with regards to excess dematerialized shares, if any	NIL					
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	N.A					
21.	Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:						

	Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
	Confirmed after 21 days.	NIL	NIL	N.A
	Pending for more than 21 days	NIL	NIL	N.A
22.	Name, Telephone & Fax No. of the Compliance Officer of the Company.	Marina Peter Company Secretary & Compliance Officer Orchid Pharma Limited “Orchid Towers”, 313 Valluvar Kottam High Road, Nungambakkam, Chennai – 600 034. Phone: (044) – 2821 1000; Fax: (044) – 2821 1002 E-mail: cs@orchidpharma.com		
23.	Name, Address, Tel. & Fax No., Regn. No. of the Auditor	P MUTHUKUMARAN AND ASSOCIATES Practising Company Secretaries, No. 16/58, 1 st Floor, 4 th Cross Street, Ganga Nagar, Kodambakkam, Chennai - 600 024. Tel: 044 - 4556 7393 Regn. No. F.C.S: 11218 C.P. No. 20333 E-mail: muthu@pmkadvisors.com		
24.	Appointment of Common Agency for share registry work	Abhipra Capital Limited Abhipra Complex A-387, Dilkhush Indl Area, G.T. Karnal Road, Azadpur, Delhi-110033. Phone: +91-11-42390783 Email: rta@abhipra.com		
25.	Any other details that the auditor may like to provide:	This report is based on the documents received online from the RTA.		

**For P MUTHUKUMARAN AND ASSOCIATES
 COMPANY SECRETARIES
 UCN: S2018TN593600**

MUTHUKUMARAN Digitally signed by MUTHUKUMARAN
 Date: 2023.07.21 16:10:15 +05'30'

**Place : Chennai
 Date : 21-07-2023
 UDIN: F011218E000655796**

**MUTHUKUMARAN
 Practising Company Secretary
 M. No. F-11218 | CP: 20333**